Tecentriq Improves Survival Rates in Metastatic TNBC Patients Who Respond to Treatment, Phase 1 Clinical Trial Suggests

Tecentriq Improves Survival Rates in Metastatic TNBC Patients Who Respond to Treatment, Phase 1 Clinical Trial Suggests
Women with metastatic triple-negative breast cancer (TNBC) who respond to the anti-PD-L1 immunotherapy Tecentriq (atezolizumab) live significantly longer than those who do not, according to data from a Phase 1 clinical trial. “Triple-negative breast cancer is an aggressive subtype of breast cancer often affecting younger women and, unfortunately, the current treatment options for metastatic disease remain limited,” Peter Schmid, MD, PhD, director of St. Bartholomew’s Breast Centre and Barts Cancer Institute in London, said in a press release. According to Schmid, the trial included the largest cohort of metastatic breast cancer patients treated with immunotherapy to date. It is also the first to report the survival outcomes of TNBC patients. Its results were presented in early April at the American Association for Cancer Research 2017 Annual Meeting, in Washington, D.C. The open-label, dose-escalation Phase 1 trial (NCT01375842) recruited metastatic TNBC patients to one of the expansion cohorts. Among the 112 patients evaluable for response, 93 had received two or more prior lines of therapy, and 19 had received Tecentriq as first-line treatment. To examine whether response rates depended on levels of PD-L1, each patient was assessed at baseline for the presence of this protein on immune cells inside the tumor. Doctors performed the test using an antibody developed by Roche. Patients fe
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.